Protective effect of brain-derived neurotrophic factor on pancreatic islets in obese diabetic mice. 2006

Mitsugu Yamanaka, and Yasushi Itakura, and Tadashi Inoue, and Atsushi Tsuchida, and Tsutomu Nakagawa, and Hiroshi Noguchi, and Mutsuo Taiji
Discovery Pharmacology Group I, Pharmacology Research Laboratories, Drug Research Division, Dainippon Sumitomo Pharma Co., Ltd., Chuo-ku, Tokyo 541-0045, Japan.

We have previously demonstrated that brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and energy expenditure in obese diabetic db/db mice. In the present study, the effect of BDNF treatment on pancreatic islets of db/db mice was examined, using vehicle-treated pair-fed db/db mice as controls. Brain-derived neurotrophic factor (10 mg/kg) or vehicle was subcutaneously administered to male db/db mice for 4 weeks. The food intake of vehicle-treated db/db mice was restricted and precisely synchronized with that of BDNF-treated db/db mice using a pellet pair-feeding apparatus because BDNF decreases food intake in hyperphagic mice. Repetitive administration of BDNF significantly lowered the blood glucose concentration compared with pair-fed vehicle-treated db/db mice. The pancreatic insulin and glucagon concentrations were measured in db/db mice to evaluate the effect of BDNF on the pancreas. Although the insulin concentration in the pancreas of pair-fed vehicle-treated db/db mice was lower than in nondiabetic control +m/+m mice, it was higher in BDNF-treated db/db mice than in vehicle-treated pair-fed db/db mice and comparable to the concentration in +m/+m mice. The glucagon concentration in the pancreas of vehicle-treated pair-fed db/db mice was higher than in +m/+m mice, and BDNF partially decreased the glucagon concentration in the pancreas of db/db mice compared with vehicle. Histologic analyses of pancreatic sections were performed to characterize the mechanism through which BDNF modulates the hormonal concentration in the pancreas of db/db mice. Although there were no significant differences in the number and total area of islets between the BDNF- and vehicle-treated groups, immunostaining with an anti-insulin antibody indicated that the islet beta-cell area in BDNF-treated db/db mice was larger than that in vehicle-treated pair-fed db/db mice. Furthermore, immunostaining with an antiglucagon antibody indicated that BDNF normalized the delocalization of non-beta cells in islets of db/db mice. Electron microscopic images of beta cells indicated a decrease in secretory granules in vehicle-treated pair-fed db/db mice; this change was reversed in BDNF-treated db/db mice and reached a level comparable to that found in +m/+m mice. These findings suggest that BDNF prevents exhaustion of the pancreas in diabetic mice by maintaining the histologic cellular organization of beta cells and non-beta cells in pancreatic islets and restoring the level of insulin-secreting granules in beta cells.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008820 Mice, Obese Mutant mice exhibiting a marked obesity coupled with overeating, hyperglycemia, hyperinsulinemia, marked insulin resistance, and infertility when in a homozygous state. They may be inbred or hybrid. Hyperglycemic Mice,Obese Mice,Mouse, Hyperglycemic,Mouse, Obese,Hyperglycemic Mouse,Mice, Hyperglycemic,Obese Mouse
D008854 Microscopy, Electron Microscopy using an electron beam, instead of light, to visualize the sample, thereby allowing much greater magnification. The interactions of ELECTRONS with specimens are used to provide information about the fine structure of that specimen. In TRANSMISSION ELECTRON MICROSCOPY the reactions of the electrons that are transmitted through the specimen are imaged. In SCANNING ELECTRON MICROSCOPY an electron beam falls at a non-normal angle on the specimen and the image is derived from the reactions occurring above the plane of the specimen. Electron Microscopy
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010179 Pancreas A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA

Related Publications

Mitsugu Yamanaka, and Yasushi Itakura, and Tadashi Inoue, and Atsushi Tsuchida, and Tsutomu Nakagawa, and Hiroshi Noguchi, and Mutsuo Taiji
September 2001, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity,
Mitsugu Yamanaka, and Yasushi Itakura, and Tadashi Inoue, and Atsushi Tsuchida, and Tsutomu Nakagawa, and Hiroshi Noguchi, and Mutsuo Taiji
January 2000, Metabolism: clinical and experimental,
Mitsugu Yamanaka, and Yasushi Itakura, and Tadashi Inoue, and Atsushi Tsuchida, and Tsutomu Nakagawa, and Hiroshi Noguchi, and Mutsuo Taiji
September 1997, Biochemical and biophysical research communications,
Mitsugu Yamanaka, and Yasushi Itakura, and Tadashi Inoue, and Atsushi Tsuchida, and Tsutomu Nakagawa, and Hiroshi Noguchi, and Mutsuo Taiji
January 2001, International journal of experimental diabetes research,
Mitsugu Yamanaka, and Yasushi Itakura, and Tadashi Inoue, and Atsushi Tsuchida, and Tsutomu Nakagawa, and Hiroshi Noguchi, and Mutsuo Taiji
January 1985, Virchows Archiv. B, Cell pathology including molecular pathology,
Mitsugu Yamanaka, and Yasushi Itakura, and Tadashi Inoue, and Atsushi Tsuchida, and Tsutomu Nakagawa, and Hiroshi Noguchi, and Mutsuo Taiji
May 1999, The American journal of otology,
Mitsugu Yamanaka, and Yasushi Itakura, and Tadashi Inoue, and Atsushi Tsuchida, and Tsutomu Nakagawa, and Hiroshi Noguchi, and Mutsuo Taiji
April 2002, Zhonghua er bi yan hou ke za zhi,
Mitsugu Yamanaka, and Yasushi Itakura, and Tadashi Inoue, and Atsushi Tsuchida, and Tsutomu Nakagawa, and Hiroshi Noguchi, and Mutsuo Taiji
January 2007, Diabetes, obesity & metabolism,
Mitsugu Yamanaka, and Yasushi Itakura, and Tadashi Inoue, and Atsushi Tsuchida, and Tsutomu Nakagawa, and Hiroshi Noguchi, and Mutsuo Taiji
March 2015, Neurological research,
Mitsugu Yamanaka, and Yasushi Itakura, and Tadashi Inoue, and Atsushi Tsuchida, and Tsutomu Nakagawa, and Hiroshi Noguchi, and Mutsuo Taiji
January 2002, Diabetes/metabolism research and reviews,
Copied contents to your clipboard!